Laser-activated transforming growth factor-b1 induces human b-defensin 2: implications for laser therapies for periodontitis and peri-implantitis Background: There is increasing popularity of high-power lasers for surgical debridement and antimicrobial therapy in the management of peri-implantitis and periodontal therapy. Removal of the noxious foci would naturally promote tissue healing directly. However, there are also anecdotal reports of better healing around routine high-power laser procedures. The precise mechanisms mediating these effects remain to be fully elucidated. This work examines these low-dose laser bystander effects on oral human epithelial and fibroblasts, particularly focusing on the role of human b-defensin 2 (HBD-2 or DEFB4A), a potent factor capable of antimicrobial effects and promoting wound healing.
Progress in the clinical management of periodontal disease spans a wide range from surgical debridement that is more effective to antimicrobial agents, immunomodulation and regenerative stem cell approaches. While the microbial etiopathogenesis in periodontal disease dominates these approaches, restoring lost periodontal tissues prosthetically with implants has become the standard of care with superior aesthesis and functions. There are few therapeutic procedures in dentistry, or clinical medicine, which offer such an impressive clinical success rate (1) . Recent innovations in implant surface topology are capable of promoting beneficial biological responses in terms of both osseointegration as well as ligament-like tissue differentiation continue to push the frontiers of regenerative dentistry (2) . However, there remain a few persistent clinical issues with implants such as periimplant mucositis (soft tissue) and peri-implantitis (bone-implant interface) (3) . The former includes the inflammatory reaction of the soft tissue surrounding the implant site, but without any bone loss around the implant. The latter process involves peri-implant bone loss usually accompanied by soft tissue inflammation and pocket formation. Both these complications of dental implants result from complex polymicrobial infection of the implant interface.
The major clinical management protocols here are similar to periodontal disease where the goal is to decontaminate and facilitate good hygiene at diseased sites to promote osseous regeneration (4, 5) . Given the complexity of the anatomical niche in periodontal defects and around implants, many approaches have been attempted to overcome the limitations of mechanical instrumentation. The use of high-power lasers as precision surgical tools allows thorough curettage of inflamed or necrotic tissues. Moreover, they can be used along with an exogenous dye to decontaminate most effectively the complex microbial microenvironments, a technique termed antimicrobial photodynamic therapy (or photoactivated disinfection) (6, 7) . During both treatments, the high-power laser illuminates the targeted zones but also exposed peri-treatment zones with lower doses generating bystander effects.
Interestingly, low-dose laser treatment has been shown to reduce inflammation and improve wound healing, including promoting osseointegration in a process termed lowlevel light/laser therapy or, more aptly, photobiomodulation therapy (8) . This latter process refers to the use of non-ionizing biophotonics devices for a non-thermal form of light therapy utilizing endogenous chromophores to promote therapeutic biological responses (9) . Despite a vast amount of basic and clinical research studies, the clinical benefits of this therapy remain equivocal due to a lack of complete understanding of its molecular mechanisms. While most emphasis has been placed on the intracellular effects of visible and near-infrared light on mitochondrial cytochrome c oxidase, our recent demonstration of an extracellular target, transforming growth factor (TGF)-b1 offers significant new opportunities. TGF-b1 is a central player in various pathophysiological processes such as development, wound healing, immunomodulation and microbial infections (10) .
Antimicrobial peptides are charged, small molecules (12-50 amino acids) demonstrating broad-spectrum effects against microbes. Among them, defensins were first described in 1966 by Zeya and Sitznagel as cationic antimicrobial peptides (11) . Human b-defensin 2 (HBD-2) has been shown to have potent antimicrobial activity against gram-negative and grampositive bacteria, fungi and viruses (12, 13) . HBD-2 can also induce chemotaxis of a wide range of immune cells, including T cells, dendritic cells, neutrophils and mononuclear cells via the chemokine receptor CCR6 (14, 15) . The purpose of this study is to examine the role of laseractivated TGF-b1 on antimicrobial peptide, HBD-2 in clinical management of periodontal and peri-implant disease.
Material and methods

Cell lines
Normal human oral keratinocytes (NOKSI) and fibroblast (HOF) cells were maintained in Dulbecco minimal Eagle's medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (Atlas Biologicals, Fort Collins, CO, USA) along with 100 units/mL penicillin and 100 lg/mL streptomycin (Life Technologies, Carlsbad, CA, USA). Cells were grown at 37°C in a humidified chamber with 5% CO 2 .
Laser treatments in cell culture
Laser treatments were performed using an 810 nm diode (GaAlAs; AMD Lasers, Indianapolis, IN, USA) for 5 min in continuous wave mode at a distance of 14.5 cm in six-well plates containing 2 mL media. Power and irradiances (W/cm 2 ) were varied to assess dose-dependent effects.
RNA extraction and polymerase chain reaction analyses
Cells were lysed in RLT buffer (Qiagen, Valencia, CA, USA) with b-mercaptoethanol and total RNA was isolated using a Qiagen RNA isolation kit (Qiagen) according to the manufacturer's protocol. For cDNA synthesis, 1 lg of RNA was reverse transcribed using ABI cDNA kit (Applied Biosystems, Foster City, CA, USA) and realtime polymerase chain reaction (PCR) quantitation was performed with Dynamo TM SYBERgreen mix (Finnzymes, Vantaa, Finland) in triplicate reactions for HBD-2 (F-5 0 -AGACT-CAGCTCCTGGTGAAGC-3 0 and R-5 0 -AGGCAGGTAACAGGATCGC -3 0 ; 59.5°C and 131 bp), RPL35A (F-5-0 AAGGGAGCACACAGCTCT TC-3 0 and R-5 0 -CTGGTTTTGTTT GGTTTGCC-3 0 ; Tm 59.5°C, 141 bp) was performed in ABI StepOne Plus (Applied Biosystems). Differential expression was determined by the formula: dCT = CT gene -CT RPL; ddCT = dCT treated -dCT untreated; fold change = 2
ÀddCT .
Western blot analysis
Cells were treated in six-well plates and washed briefly with Dulbecco's phosphate-buffered saline (Gibco, Waltham, MA, USA) and lysed in RIPA lysis buffer containing protease inhibitor cocktail (both, SigmaAldrich). Total protein was determined using the BCA reagent (Pierce, Waltham, MA, USA). Equal amounts of total protein were resolved on sodium dodecyl sulfatepolyacrylamide gel electrophoresis gels, transferred to polyvinylidene difluoride membrane and immunoblotted. To block non-specific binding sites, blots were incubated in blocking buffer (Licor, Lincoln, NE, USA) for 1 h followed by overnight incubation in primary antibodies (phospho-Smad2, phospho-AKT from Cell Signaling Technology, human defensin 2 from Abcam and b-Actin, tubulin from Sigma) at 4°C. Next day, blots were washed in Trisbuffered saline three times (10 min each), followed by incubation with secondary antibody (antirabbit or antimouse IRDye 800 or 680 CW, Licor 1 : 10,000) for 1 h. Following washes, bands were visualized using Odyssey Imaging Systems (Licor) and quantitated using ALPHAIMAGER software (ProteinSimple, San Jose, CA, USA).
Immunocytochemistry
Cells were plated in chamber slides (Nunc, Waltham, MA, USA) and treated with specified conditions. Following incubation for 24 h, cells were fixed and permeabilized in chilled methanol for 5 min at À20°C. Following blocking, incubation with primary antibody (human defensin 2 from Abcam, 1 : 100) incubated overnight at 4°C. The following day, cells were washed and incubated with secondary (antirabbit 488; Jackson ImmunoResearch, West Grove, PA, USA) for 1 h, washed and mounted with DAPI aqueous mount (Life Technologies) and slides were imaged with a fluorescent microscope (Zeiss, Dublin, CA, USA).
Statistical analyses
Statistical analyses were performed in GRAPHPAD PRISM software (GraphPad Software, Inc., La Jolla, CA, USA). Significance was assessed using the non-parametric Mann-Whitney or Kruskal-Wallis test. All treatments were compared to untreated control and p < 0.05 was considered significant.
Results
Laser induces human b-defensin 2 expression
We first assessed the ability of lowpower laser treatments to induce HBD-2 isoforms using quantitative reverse transcription-PCR analysis. We observed that laser treatments robustly induced HBD-2 expression in oral fibroblast cell line compared to milder expression in the keratinocyte cell line (Fig. 1A) . We further varied laser irradiance and noted a dosedependent induction of HBD-2 expression with optimum induction at a total fluence of 4 J/cm 2 for 300 s followed by a decrease at higher doses (Fig. 1B) . We further validated these observations by immunoblotting and immunostaining for HBD-2 ( Fig. 1C  and 1D ). These observations indicate that low-dose laser treatment was able to induce a potent antimicrobial peptide, HBD-2, in oral fibroblasts.
Induction of human b-defensin 2 by laser treatment is via transforming growth factor-b1 TGF-b1 has been known to induce HBD-2 expression in a wide range of cells types in the oral cavity, including keratinocytes, fibroblasts, neutrophils and endothelial cells (16) (17) (18) . We first inquired if TGF-b1 is able to induce HBD-2 expression in our cell lines and noted robust induction in oral fibroblasts ( Fig. 2A) . We had recently reported the ability of low-power laser-generated reactive oxygen species to activate latent TGF-b1 (19) . Therefore, we next asked if the laserinduced HBD-2 expression was mediated via TGF-b. Pre-incubation of oral fibroblasts with a TGF-b receptor 1 (Alk5) inhibitor before laser treatments resulted in abrogation of the increased HBD-2 expression (Fig. 2B) . To investigate further the laser activation of the TGF-b pathway, we assessed expression of another downstream target named TGF-b induced. We observed similar upregulation of TGF-b-induced expression (Fig. 2C) indicating that the laser-activated TGF-b induces multiple downstream gene expression. These results suggest that low-dose laser treatments results in activation of the TGF-b1 pathway that mediates HBD-2 expression.
Lasers activates both canonical and non-canonical transforming growth factor-b signal transduction
The TGF-b ligand binds to its transmembrane serine-threonine receptor (TGF-bRII) that forms a complex with another receptor, the TGF-bRI or ALK5, leading to intracellular downstream signaling. The cytoplasmic signaling intermediates recruited to the activated receptor complex are broadly categorized as the canonical Smads or the noncanonical arm, including Akt, MAPKs (JNK, p38 or ERK), TAK among others (Fig. 3A) (20-23) . Crosstalk between the two arms, along with individual cell lineage transcriptional profile, appears to contribute to a broad range of TGF-b responses (24, 25) . Therefore, we next examined activation of the canonical and non-canonical signaling pathways by laser treatments. We noted that laser treatments of oral fibroblasts results in increased phospho-smad2 and phospho-AKT levels (Fig. 3B ). This indicates both arms of TGF-b signal transduction pathways are activated by low-dose laser treatments.
Human b-defensin 2 expression utilizes concerted transforming growth factor-b signaling
To dissect further the contribution of these individual signaling arms to HBD-2 expression, we first verified the specificity of these inhibitors to block respective signaling arms (Fig. 4A) . Then, we pretreated the oral fibroblast cell lines with either TGF-bRI or AKT inhibitor followed by laser treatments. We noted both inhibitors were able to block the laser-induced HBD-2 expression (Fig. 4B) . This suggests that laseractivated TGF-b1 induces HBD-2 expression via both Smad (canonical) and non-Smad (non-canonical) TGFb signaling pathways.
Discussion
Clinical success with oral implants is based on a large number of factors but its biological foundation predominantly hinges on robust integration of the implant-tissue interface without clinical signs and symptoms of infection or inflammation. The process of osseointegration involves a sequence of well-orchestrated biological responses initiated following implant placement involving immediate, rapid deposition of blood and interstitial fluid followed by amorphous deposition of proteoglycans and randomly aligned collagen and finally, direct bone apposition (26) . The intricate complexity of cell signaling networks involving growth factors (e.g. bone morphogenetic protein, Hedgehog, fibroblast growth factor, Notch and Wnt) and transcriptional factors (e.g. Sox9, Runx2 and Osterix) have all been shown to have pivotal roles in driving peri-implant tissue healing and regeneration gene expression signatures that are being investigated to enable better, predictive clinical responsiveness (27, 28) . There is increased recognition of the predominant foreign body reaction that implants represent within the jaw bones characterized by a prominent inflammatory cytokine expression as well as discrete transcriptional responses such as those involving Per-ARNT-Sim proteins and Per2 (circadian rhythm) expression (29, 30) . The initial inflammation-immune processes are critical in determining the success of the biological sequela at the implant interface. However, successful osseointegration and long-term clinical success necessitates eventual resolution of these acute processes and robust healing.
Current prevalence of peri-implant disease appears to vary from 28% to 56% but the severity and extent of tissue destruction varies greatly due to a multitude of factors (31) . Persistent inflammation due to differences in physical characteristics of the metal implant interface, non-ideal clinical implant placement techniques and presence of pathogenic polymicrobial infections (32, 33) . All of these factors appear to act in concert and can be clinically detrimental in implant success. Supporting implant therapy, besides initial implant cost, is a major determinant of clinical cost-effectiveness (33) . Despite some difference in the microbiome and histopathology between periodontitis and peri-implantitis, clinical management strategies have similar objectives, which are to reduce the infection causing microbiota, improve selfcleansing anatomy and promote tissue healing and regeneration (34, 35) .
Lasers are currently used for a wide range of applications in clinical dentistry (36, 37) . The rationale for their use in the management of periodontal and peri-implant disease has been proposed to be threefold: first, to reduce damaged or inflamed tissues via surgical curettage of granulation tissues; second, antimicrobial effects on disease biofilms in conjunction with an exogenous dye (antimicrobial photodynamic therapy/photoactivated disinfection); and, thirdly, using lowdose lasers to reduce inflammation and promote tissue regeneration (photobiomodulation) (38, 39) (Fig. 5) . This study demonstrates one of the plausible mechanisms involved in the use of lasers in these clinical scenarios. The directed use of high laser energy, with or without exogenous dyes, can clearly be detrimental to microorganisms. Some clinical protocols currently advocate the use of low-dose laser treatments after surgical debridement. However, the potential benefits and mechanisms of these bystander low-dose laser effects in these contexts have not yet been carefully investigated.
We examined these low-dose laser effects with the rationale that the tissues adjacent to high-power laser treatment zones would evoke potent bystander biological responses. We had recently noted the ability of lowpower lasers to activate endogenous latent TGF-b1 (19) . TGF-bs have a central role in mediating a diverse range of biological functions in wound healing such as cell migration, proliferation, secretion, differentiation and functions of a broad range of cell types (40, 41) . However, TGF-b appears to have distinct effects on individual cell populations in a context-dependent manner. While TGF-b promotes re-epithelization of wounds by promoting keratinocyte migration, it also stimulates extracellular matrix deposition and wound contraction by myofibroblasts (42, 43) . Further, it has potent immunomodulatory roles, both stimulating and inhibiting T cells depending on the cellular milieu (44) . A distinct immunosuppressive role for TGF-b includes its ability to drive development of regulatory T cells via expression of the transcription factor Foxp3.
TGF-b1 has multiple roles in bone pathophysiology and is a key player in osseointegration (45, 46) . Laser-activated endogenous TGF-b could potentially harness many of its immunomodulation and wound healing responses in resolving peri-implantitis and promoting osseointegration. Given the potent immunomodulatory roles of TGF-bs, this study investigated one of the downstream targets, HBD-2 that would have direct antimicrobial effects as well as indirectly modulate inflammation and promote tissue regeneration in the peri-implant or periodontal tissues. b-Defensins are small, cysteine-rich, positively charged peptides that have broad antimicrobial activity (16) . Of the four HBD isoforms described, three have been reported to be expressed in the oral mucosa. While HBD-1 is constitutively expressed, the other two isoforms, HBD-2 and HBD-3, can be induced by microbial components, such as lipopolysaccharide, and inflammatory mediators such as interleukins 1a and 1b, tumor necrosis factor-a and TGF-b (47) (48) (49) . Before this report with near-infrared lasers, the only form of electromagnetic radiation capable of inducing HBD-2 expression was high energy, ionizing ultraviolet radiation (50) . Interestingly, it has been noted that ultraviolet treatments downregulate HBD-2 expression in psoriasis and scleroderma while cells from distinct anatomical sites do not respond, similarly suggesting HBD-2 expression could be context-dependent irrespective of the stimuli. The major limitation of this study was the use of spontaneously immortalized cell lines that were readily available for these analyses. Examining the effects of laser treatments of HBD-2 expression in primary cells as well as in vivo analyses, in the appropriate clinical contexts, would be ideal areas of future investigations. The lack of responsiveness of the keratinocyte cell line can perhaps be attributed to the specific cell line rather than a feature of epithelial responsiveness and requires further exploration. In conclusion, this study demonstrates the ability of laser treatments to induce expression of a potent antimicrobial peptide HBD-2. This provides a mechanistic rationale for optimization of the use of lasers in effective clinical management strategies for peri-implant and periodontal disease.
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